Xofigo is the first alpha particle-emitting radioactive therapeutic agent that has showed improvement in overall survival (OS) and delay in time to first symptomatic skeletal event (SSE) compared
This is the second agreement with QIAGEN within nine months; the first licence agreement was signed for the amplification buffer technology developed by the team led by renowned
Nexavar (sorafenib) tablet is an anticancer medicine for the treatment of patients with unresectable HCC. Stivarga is an inhibitor of multiple kinases involved in normal cellular functions and
The enrolment of the first patient in Phase 1b/2 INvestigation of anti-Notch Antibody therapy with Cisplatin and etoposide in small cell Lung carcinoma Efficacy and safety (PINNACLE) trial
The central alpha2A-adrenergic receptor agonist is indicated as monotherapy and adjunctive therapy to stimulant medications for Attention De?cit Hyperactivity Disorder (ADHD). TWi Pharmaceuticals president Dr. Calvin Chen said,
According to the license and supply deal, Ligand has earned a $500,000 milestone payment. Ligand executive vice president and chief operating officer Matthew Foehr said, "Rib-X is an
The investigational therapy that is currently in Phase 2 development comprises two recombinant, gluten specific enzymes (a cysteine protease (EP-B2) and a prolyl endopeptidase (PEP)), that degrade gluten
The company has added on-site stability storage and additional GMP testing that aids in manufacturing good-quality supplies for clinical use. Bend Research vice president Tanya Hayden said the
The new rotavirus vaccine is expected to be made available at a cost of around $1 per dose, allowing poor countries to easily vaccinate their children against the
The patent application ‘Alpha Emitting Constructs and Uses Thereof’ is licensed by Actinium from Memorial Sloan Kettering Cancer Center. Actinium CMO Dragan Cicic said the decision is important
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.